Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Enrolling by invitation Observational

Prospective Aortic Biobank of POP-STAR

NCT04269447 · tracked via the Priya Life Science Sweden tracker
Phase
Observational
Started
2019-11-18
Last updated
2026-04-08

Condition(s) studied

Abdominal Aortic Aneurysm Without RuptureAbdominal Aortic Aneurysm, RupturedAortic AneurysmAneurysm AbdominalAneurysm

Investigational drug(s) / intervention(s)

Structured imaging follow-up

Structured imaging follow-up: Structured imaging follow-up protocol with ultrasound (US) and computed tomography (CT) examinations as compared to current standard surveillance protocol for individualized estimations of AAA growth.

Study summary

The overall objective of the POP-STAR project is individualized surveillance for patients diagnosed with abdominal aortic aneurysms by means of more precise, patient-specific AAA growth prediction.

Eligibility

Sex
ALL
Min age
50 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Abdominal aortic aneurysm 35-49 mm in men * Abdominal aortic aneurysm 30-49 mm in women Exclusion Criteria: * Previous aortic or iliac surgery * Present comorbidities with less than 2-years life expectancy * Unable or unwilling to give informed consent * Computed tomography examination with intravenous contrast contraindicated due to renal insufficiency (defined as creatinine/eGFR level XXX)

Primary outcome measure(s)

  • Aneurysm expansion rate — Primary outcome evaluated at two years of follow-up.
    Comparison of correctness of predicted growth (diameter vs ASI)
  • Aneurysm expansion rate — Primary outcome second analysis at two years follow-up.
    Assessment if a more correct predicted growth alters surveillance (ASI vs diameter)

Trial sites (2)

FacilityCityRegionStatus
Department of Vascular Surgery, Karolinska University Hospital Solna Stockholm County
Karolinska University Hospital Stockholm Sweden

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04269447 on ClinicalTrials.gov ↗ ← All trials in Sweden